Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a heart drug beat a deadly blood infection? new trial aims to find out

NCT ID NCT07384702

Disease control Sponsor: Fundación Pública Andaluza para la gestión de la Investigación en Sevilla Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether adding clopidogrel, a drug usually used to prevent blood clots, to standard antibiotics improves outcomes for adults with a serious Staphylococcus aureus bloodstream infection. About 230 hospitalized patients will be randomly assigned to receive clopidogrel or not, and researchers will track survival, recovery, and side effects. The goal is to see if this combination leads to better overall results than antibiotics alone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

About 230 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Jun 2026

An estimate. Start dates often move.

Expected to finish

Jun 2030

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: To be eligible, patients must meet the same criteria as those of the general SNAP platform, as well as the domain-specific criteria: * Microbiological isolation: Presence of Staphylococcus aureus complex in at least one blood culture. * Hospitalization status: The patient must be admitted to a participating hospital at the time of eligibility assessment. * Time window: Eligibility assessment must be completed within 72 hours after collection of the initial blood culture. Exclusion Criteria: General Medical and Safety Factors: * Allergies: Known hypersensitivity to thienopyridines (clopidogrel, prasugrel, ticlopidine). * Clinical status: Inability to tolerate or take oral medications, and severe hepatic impairment (Child-Pugh Class C). * Pregnancy: Pregnant or breastfeeding women. High Risk of Bleeding or Hematologic Disorders: * Active or recent bleeding: Significant bleeding or invasive procedures within the previous 7 days. * Planned surgeries: Requirement for major surgical intervention within 10 days following study enrollment. * Coagulation parameters: Platelet count \<50,000/mm³ or known coagulation disorders. * Concomitant medications: Patients already receiving regular aspirin therapy, other P2Y12 inhibitors, or therapeutic-dose anticoagulants (prophylactic-dose heparin is permitted). Specific Diagnoses and Clinical Criteria: * Endocarditis: Confirmed diagnosis or clinical suspicion of bacterial endocarditis. Sources indicate that exclusion of endocarditis is justified because the potential benefit of clopidogrel is expected during early phases of high bacterial burden, whereas bleeding risk increases with prolonged treatment or established deep-seated infections. * Medical judgment: If the treating clinical team determines that participation in this domain is not in the patient's best interest.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Bacteremia due to staphylococcus aureus are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

staphylococcal infection staphylococcus aureus infection

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Bacteremia due to staphylococcus aureus

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    20 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • H.U. Clinic

    Barcelona, Spain

  • H.U. Jerez de la Frontera

    Jerez de la Frontera, Spain

  • H.U. Mutua Terrassa

    Barcelona, Spain

  • H.U. Reina Sofía

    Córdoba, Spain

  • H.U. Virgen del Rocío

    Seville, Spain

  • Hospital General Universitario de Alicante

    Alicante, Spain

  • Hospital Universitario Bellvitge

    Barcelona, Spain

  • Hospital Universitario La Princesa

    Madrid, Spain

  • Hospital Universitario La paz

    Madrid, Spain

  • Hospital Universitario Lozano Blesa

    Zaragoza, Spain

  • Hospital Universitario Marqués de Valdecilla

    Valdecilla, Spain

  • Hospital Universitario Ramon y Cajal

    Madrid, Spain

  • Hospital Universitario San Cecilio

    Granada, Spain

  • Hospital Universitario Son Espases

    Palma de Mallorca, Spain

  • Hospital Universitario Vall d'Hebron

    Barcelona, Spain

  • Hospital Universitario Virgen de Valme

    Seville, Spain

  • Hospital Universitario de la Santa Creu i Sant Pau

    Barcelona, Spain

  • Hospital Universitario Álvaro Cunqueiro

    Vigo, Spain

  • Hospital Virgen Macarena

    Seville, 41008, Spain

  • Hospital del Mar

    Barcelona, Spain

More trials for these conditions

Other studies related to the condition(s) this trial covers.